AKVA group ASA
AKVA group ASA: Update cyber-attack
As communicated January 10, AKVA group (“AKVA” or “the company”), has been subject to a severe cyber-attack where several key systems were shut down.
AKVA’s technical team, with support from external expertise, has detected the root cause of the system shut-down and will gradually restore the IT systems. Further information about the incident and the remedies deployed will not be made available as the police is still investigating the incident.
AKVA has in a short time made significant efforts to review IT security and ensure a secure operating environment for the group's IT systems.
The company and its subsidiaries will be operative while restarting the IT systems, but manual operations will still be required for a period.
It is too early to assess the financial impact of the cyber-attack, but the company will incur significant non-recurring costs during Q1 2021 related to the cyber-attack and mitigating measures. Further details will be reported in connection with the presentation of the Q4 results on February 19, 2021.
Dated: 18 January 2021
AKVA group ASA
|Knut Nesse||Chief Executive Officer|
|Phone:||+47 51 77 85 00|
|Mobile:||+47 91 37 62 20|
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Norsk Hydro5.3.2021 07:32:40 CET | Press release
Norsk Hydro: Invitation to Investor presentation - Hydro agrees to sell Rolling business area to KPS Capital Partners
Aktieselskabet Schouw & Co.5.3.2021 07:32:10 CET | Press release
Annual Report 2020: The conglomerate shows its strength
Aktieselskabet Schouw & Co.5.3.2021 07:32:00 CET | Pressemeddelelse
Årsrapport 2020: Konglomeratet viser sin styrke
Norsk Hydro5.3.2021 07:31:49 CET | Press release
Norsk Hydro: Hydro agrees to sell Rolling business area to KPS Capital Partners for EUR 1,380 million
Heijmans NV5.3.2021 07:31:39 CET | Press release
Heijmans and AM join forces in Feyenoord City Rotterdam
Hyloris Pharmaceuticals5.3.2021 07:02:18 CET | Press release
Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets
F. Hoffmann-La Roche Ltd5.3.2021 07:02:08 CET | Press release
Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom